RT Journal Article
SR Electronic
T1 Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.06.21261716
DO 10.1101/2021.08.06.21261716
A1 Kant, Rajni
A1 Dwivedi, Gaurav
A1 Zaman, Kamran
A1 Sahay, Rima R
A1 Sapkal, Gajanan
A1 Kaushal, Himanshu
A1 Nyayanit, Dimpal A.
A1 Yadav, Pragya D
A1 Deshpande, Gururaj
A1 Singh, Rajeev
A1 Chaowdhary, Sandeep
A1 Gupta, Nivedita
A1 Kumar, Sanjay
A1 Abraham, Priya
A1 Panda, Samiran
A1 Bhargava, Balram
YR 2021
UL http://medrxiv.org/content/early/2021/08/07/2021.08.06.21261716.abstract
AB Immunization program against COVID-19 in India started with two vaccines; AstraZeneca’s ChAdOx1-nCov-19 (termed Covishield in India) and inactivated whole virion BBV152 (Covaxin); homologous prime-boost approach was followed. However, eighteen individuals, under the national program, inadvertently received Covishield as the first jab and Covaxin as the second. We compared the safety and immunogenicity profile of them against that of individuals receiving either Covishield or Covaxin (n=40 in each group). Lower and similar adverse events following immunization in all three groups underlined the safety of the combination vaccine-regime. Immunogenicity profile against Alpha, Beta and Delta variants in heterologous group was superior; IgG antibody and neutralising antibody response of the participants was also significantly higher compared to that in the homologous groups. The findings suggest that immunization with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was conducted with intramural funding COVID-19 of Indian Council of Medical Research (ICMR) New Delhi provided to ICMR-RMRC Gorakhpur and ICMR-National Institute of Virology Pune. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee of the ICMR-Regional Medical Research Centre (ICMR-RMRC), Gorakhpur, Uttar Pradesh, India. (IHEC Number-RMRCGKP/EC/2021/2.1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data pertaining to this study is available with the Corresponding Author.